Efficacy of Buteyko Breathing in Seniors With Chronic Eustachian Tube Dysfunction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Buteyko breathing, usual care.
- Who it may be relevant to
- Registry conditions: Eustachian Tube Dysfunction. Basic parameters: 65 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Eustachian tube dysfunction is distressing probelm. drugs usually are not effective. compelemtary tehrapies like Buteyko breathing may be effective
Detailed description
forty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I or group II. the group enroled 20 seniors. both groups wil take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks.
Interventions
- Other Buteyko breathing
twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group I and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks. Also, group I will aslo receive 30-min Buteyko breathing two times daily for 14 weeks. - Other usual care
twenty seniors with Eustachian tube dysfunction (chronic obstructive form) will be ranomized to group II and this group will take usual care (budesonide spray in nose in 64 microgram concentration one time per day plus the intake of a tablet two times daily containing containing 20-mg contration of pseudoephedrine hydrochloride and 5-mg concentration of loratadine) for 2 weeks.
Primary outcome measures
- Eustachian Tube Dysfunction Questionnaire [Time frame: it will be measured after 2 weeks]
Secondary outcome measures (10)
- systolic blood pressure [Time frame: it will be measured after 2 weeks]
- diastolic blood pressure [Time frame: it will be measured after 2 weeks]
- respiratory rate [Time frame: it will be measured after 2 weeks]
- pulse rate [Time frame: it will be measured after 2 weeks]
- patient health questionnaire [Time frame: it will be measured after 2 weeks]
- state trait anxiety inventory [Time frame: it will be measured after 2 weeks]
- perceived stress scale [Time frame: it will be measured after 2 weeks]
- short form 36 questionnaire [Time frame: it will be measured after 2 weeks]
- profile of mood satus [Time frame: it will be measured after 2 weeks]
- percenatge of tympanometry (type C) [Time frame: it will be measured after 2 weeks]
Eligibility criteria
Inclusion criteria
- Eustachian Tube Dysfunction (chronic obstructive form)
- unilateral ear affetion
- senior patients
- chronci affection more than 3 months
Exclusion criteria
- obesity
- cardiac probelms repsiratory problems
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Cairo University — Dokki
Identifiers
NCT: NCT07193485 · IRB00014233-36